Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) FCF Margin (2016 - 2025)

Historic FCF Margin for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to 27.35%.

  • Cytosorbents' FCF Margin rose 30100.0% to 27.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 27.09%, marking a year-over-year increase of 264600.0%. This contributed to the annual value of 41.33% for FY2024, which is 300600.0% up from last year.
  • Cytosorbents' FCF Margin amounted to 27.35% in Q3 2025, which was up 30100.0% from 13.48% recorded in Q2 2025.
  • Over the past 5 years, Cytosorbents' FCF Margin peaked at 13.48% during Q2 2025, and registered a low of 131.11% during Q2 2022.
  • Over the past 5 years, Cytosorbents' median FCF Margin value was 54.23% (recorded in 2024), while the average stood at 55.77%.
  • Its FCF Margin has fluctuated over the past 5 years, first crashed by -1076200bps in 2022, then surged by 797000bps in 2023.
  • Over the past 5 years, Cytosorbents' FCF Margin (Quarter) stood at 65.14% in 2021, then rose by 9bps to 59.14% in 2022, then decreased by -27bps to 75.02% in 2023, then soared by 65bps to 26.34% in 2024, then fell by -4bps to 27.35% in 2025.
  • Its FCF Margin was 27.35% in Q3 2025, compared to 13.48% in Q2 2025 and 42.6% in Q1 2025.